SLAMF1 and CD180 are considered positive CD20 expression regulators that may promote the responsiveness of SLAMF1+CD180+ B cell CLL to cancer immunotherapies based on CD20 targeted therapy (123). Here, SLAMF1 is linked to B-cell chronic lymphocytic leukemia.